FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLC :

The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.

Related Keywords

New York , United States , Memorial Sloan Kettering Cancer Center , Gregory Riely , Foundationone Cdx , Drug Administration , Pfizer , Array Biopharma , Foundationone Liquid , New York City , Lung Cancer , Ung Carcinoma , Ancer Lung , Melanoma , Malignant Melanoma , Skin Cancer , Alignant Skin Neoplasm , Kbraf , Non Small Cell Lung Cancer , Nsclc , Braf Inhibitors , B Raf Inhibitors , Small Cell Lung Cancer , Targeted Therapy , Biologic Therapy , Cancer , Alignant Neoplasia , Arcinoma , Tumor , Pain Management , Abdominal Pain , Intracranial Hemorrhage , Intracranial Bleeding , Dyspnea , Gus F ,